What is Tesamorelin?
Tesamorelin is a growth-hormone-releasing factor analogue. In the United States, prescription tesamorelin is approved to reduce excess abdominal fat in adults with HIV and lipodystrophy; it is not approved as a general weight-loss, bodybuilding or anti-ageing drug.
Proposed mechanism
Tesamorelin stimulates pituitary growth-hormone secretion through the GHRH receptor, increasing downstream IGF-1. Its clinical development focused on visceral adipose tissue in HIV-associated lipodystrophy.
What has been published?
Randomized placebo-controlled studies found reductions in visceral adipose tissue in adults with HIV-associated abdominal fat accumulation. A smaller randomized study also reported reductions in visceral and liver fat.
Current human evidence
Tesamorelin has substantially stronger human evidence than most compounds in research-peptide markets, but that evidence is indication-specific. It should not be extrapolated automatically to general fat loss, performance or longevity.
Regulatory status
FDA lists tesamorelin products under the EGRIFTA reference product, originally approved in 2010. Current EGRIFTA WR labeling states it is used to reduce excess abdominal fat in HIV-infected adults with lipodystrophy and is not for weight-loss management.
Possible areas of research interest
- HIV-associated lipodystrophy
- Visceral adipose tissue
- GHRH/GH/IGF-1 physiology
- Liver-fat research
Important limitations
- Approval is for a specific clinical population and indication
- Not approved for general weight management
- Long-term cardiovascular safety is not established in the label
- GH/IGF-1 effects require medical risk assessment
References
AEVLI prioritizes primary publications and regulator materials over anecdotal claims.